In this study, we formulated a microparticulate melanoma cancer vaccine via the transdermal route. The vaccine was delivered using microneedle-based Dermaroller® which is available for cosmetic purposes. Unlike subcutaneous injections, administration using microneedles is painless and in general can increase the permeability of many compounds ranging in size from small molecules to proteins and microparticles that do not normally penetrate the skin. The vaccine microparticles were taken up by the antigen presenting cells which demonstrated a strong IgG titre level of 930 ug/mL in serum samples. The formulation increased the immunogenicity of the vaccine by incorporating the antigen into an albumin matrix having a size range of around 0.63-1.4 µm which acted as a synthetic adjuvant. The animals were vaccinated with 1 prime and 4 booster doses administered every 14 days over 8 weeks duration, followed by challenge with live tumour cells which showed protection after transdermal vaccination.

中文翻译：

---

使用透皮递送的新型黑色素瘤微粒疫苗。

在这项研究中，我们通过透皮途径配制了微粒黑色素瘤癌症疫苗。使用基于微针的Dermaroller®运送疫苗，该疫苗可用于美容目的。与皮下注射不同，使用微针给药无痛，并且通常可以增加许多化合物的渗透性，从小分子到蛋白质和通常不渗透皮肤的微粒，大小不一。疫苗微粒被​​抗原呈递细胞吸收，该抗原呈递细胞在血清样品中显示出930 ug / mL的强IgG滴度。该制剂通过将抗原掺入大小范围为约0.63-1.4μm的白蛋白基质中来增加疫苗的免疫原性，所述白蛋白基质充当合成佐剂。